Seed Outlook and Crop Varieties for 1960

Using high-quality seed of adapted and tested varieties is an important part of good farming in 1960 or any year. New to this section this year is the outlook for seed of some of the varieties you may wish to plant

February 1967 Conference Issue

Massachusetts Turf and Lawn Grass CouncilBetter Turf Through Research and Educatio

1966

Proper Watering by Earl P. Grey (page 1) Soil Structure and Plant Feeding for Trees and Shrubs on the Golf Course by William Teece (2) Power Golf Carts: A Blessing or a Curse by David Dunlavey (3) A Comparison by Paul White (3) Trees on a Golf Course by Oliver Leech (5) Turf Management Majors Want a Golf Team by Richard Rossiter (6) Class Will of \u2766 (7)Famous Last Words from 1966 (8) Turf Heating with Electric Cables by J.R. Barrett, Jr. and W.H. Daniel (A-1) Poa Annua Restriction by C. F. Kerr and W.H. Daniel (A-9) Phosphorus by Marvin H. Ferguson (A-14) Role of Potassium in Turf Grass management by R. E. Wagner (A-16) Role of Minor Elements in Turfgrass Management by Alexander Radko (A-22) Rhizoctonia Brown patch and Pythium Diseas by Malcolm C. Shurtleff (A-27) Sclerotinia Dollar Spot and Snow Mold by Noel Jackson (A-32) Fusarium Blight - Disease of Turf Grasses by George A. Bean (A-35) Observing the Weather - Old and New Techniques by Robert C. Copeland (A-39) Water Supply by Allan Grieve Jr. (A-41) Establishment and Maintenance of Campus Turf by William A. Lambert (A-51) Athletic Field Management by J. T. Williams (A-56

Genetic Determinants of Virulence in Pathogenic Lineage 2 West Nile Virus Strains

The most likely determinants are mutations in the nonstructural proteins encoding viral replication and protein cleavage mechanisms

The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.

Infant acute lymphoblastic leukemia (ALL) with MLL rearrangements (MLL-R) represents a distinct leukemia with a poor prognosis. To define its mutational landscape, we performed whole-genome, exome, RNA and targeted DNA sequencing on 65 infants (47 MLL-R and 18 non-MLL-R cases) and 20 older children (MLL-R cases) with leukemia. Our data show that infant MLL-R ALL has one of the lowest frequencies of somatic mutations of any sequenced cancer, with the predominant leukemic clone carrying a mean of 1.3 non-silent mutations. Despite this paucity of mutations, we detected activating mutations in kinase-PI3K-RAS signaling pathway components in 47% of cases. Surprisingly, these mutations were often subclonal and were frequently lost at relapse. In contrast to infant cases, MLL-R leukemia in older children had more somatic mutations (mean of 6.5 mutations/case versus 1.3 mutations/case, P = 7.15 × 10(-5)) and had frequent mutations (45%) in epigenetic regulators, a category of genes that, with the exception of MLL, was rarely mutated in infant MLL-R ALL

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.

Ebolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity

RNA delivery by extracellular vesicles in mammalian cells and its applications.

The term 'extracellular vesicles' refers to a heterogeneous population of vesicular bodies of cellular origin that derive either from the endosomal compartment (exosomes) or as a result of shedding from the plasma membrane (microvesicles, oncosomes and apoptotic bodies). Extracellular vesicles carry a variety of cargo, including RNAs, proteins, lipids and DNA, which can be taken up by other cells, both in the direct vicinity of the source cell and at distant sites in the body via biofluids, and elicit a variety of phenotypic responses. Owing to their unique biology and roles in cell-cell communication, extracellular vesicles have attracted strong interest, which is further enhanced by their potential clinical utility. Because extracellular vesicles derive their cargo from the contents of the cells that produce them, they are attractive sources of biomarkers for a variety of diseases. Furthermore, studies demonstrating phenotypic effects of specific extracellular vesicle-associated cargo on target cells have stoked interest in extracellular vesicles as therapeutic vehicles. There is particularly strong evidence that the RNA cargo of extracellular vesicles can alter recipient cell gene expression and function. During the past decade, extracellular vesicles and their RNA cargo have become better defined, but many aspects of extracellular vesicle biology remain to be elucidated. These include selective cargo loading resulting in substantial differences between the composition of extracellular vesicles and source cells; heterogeneity in extracellular vesicle size and composition; and undefined mechanisms for the uptake of extracellular vesicles into recipient cells and the fates of their cargo. Further progress in unravelling the basic mechanisms of extracellular vesicle biogenesis, transport, and cargo delivery and function is needed for successful clinical implementation. This Review focuses on the current state of knowledge pertaining to packaging, transport and function of RNAs in extracellular vesicles and outlines the progress made thus far towards their clinical applications

Bowel management for the treatment of pediatric fecal incontinence

Fecal incontinence is a devastating underestimated problem, affecting a large number of individuals all over the world. Most of the available literature relates to the management of adults. The treatments proposed are not uniformly successful and have little application in the pediatric population. This paper presents the experience of 30 years, implementing a bowel management program, for the treatment of fecal incontinence in over 700 pediatric patients, with a success rate of 95%. The main characteristics of the program include the identification of the characteristics of the colon of each patient; finding the specific type of enema that will clean that colon and the radiological monitoring of the process